

# Amelia Ruffatti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7847151/publications.pdf>

Version: 2024-02-01

88  
papers

4,747  
citations

109264

35  
h-index

98753

67  
g-index

90  
all docs

90  
docs citations

90  
times ranked

3175  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 346-353.	2.9	2
2	High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
3	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Expertsâ€™ Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	2.5	38
4	The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 28-35.	1.6	18
5	The first thrombotic event in purely obstetric antiphospholipid syndrome patients and in antiphospholipid antibody carriers: comparison of incidence and characteristics. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 455-461.	0.8	10
6	Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome. <i>Blood</i> , 2021, 137, 2989-2992.	0.6	4
7	Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients. <i>Arthritis Research and Therapy</i> , 2021, 23, 134.	1.6	4
8	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. <i>Rheumatology</i> , 2020, 59, 1306-1314.	0.9	53
9	Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 036-043.	1.8	11
10	Insights into the pathogenesis of catastrophic antiphospholipid syndrome. A case report of relapsing catastrophic antiphospholipid syndrome and review of the literature on ischemic colitis. <i>Clinical Rheumatology</i> , 2020, 39, 1347-1355.	1.0	12
11	Fluorinated steroids are not superior to any treatment to ameliorate the outcome of autoimmune mediated congenital heart block: a systematic review of the literature and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 783-791.	0.4	5
12	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. <i>Frontiers in Immunology</i> , 2019, 10, 1948.	2.2	33
13	Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome. <i>American Journal of Reproductive Immunology</i> , 2019, 82, e13185.	1.2	14
14	Therapeutic apheresis during pregnancy: A single center experience. <i>Transfusion and Apheresis Science</i> , 2019, 58, 652-658.	0.5	23
15	An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz005.	0.3	9
16	First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 11.	1.1	39
17	Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. <i>Autoimmunity Reviews</i> , 2019, 18, 561-563.	2.5	25
18	IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. <i>Thrombosis Research</i> , 2019, 177, 157-160.	0.8	30

#	ARTICLE	IF	CITATIONS
19	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , 2019, 18, 406-414.	2.5	106
20	AB0165â€¦THE EUROPEAN REGISTRY ON OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (EUROAPS): A SURVEY OF 1100 CONSECUTIVE CASES. , 2019, , .		2
21	â€œDisease knowledge indexâ€•and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 475-481.	0.8	25
22	Management of pregnant women with antiphospholipid antibodies. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 347-358.	1.3	18
23	European families reveal MHC class I and II associations with autoimmune-mediated congenital heart block. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1381-1382.	0.5	6
24	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2018, 47, 639-646.	1.8	62
25	Detection of autoantibodies to the p200-epitope of SSA/Ro52 antigen. A comparison of two laboratory assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 927-932.	1.4	2
26	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. <i>Journal of Autoimmunity</i> , 2018, 90, 1-27.	3.0	60
27	Beyond thrombosis: Anti-Î²2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018, 90, 76-83.	3.0	60
28	Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. <i>Medicina ClÃnica</i> , 2018, 151, 215-222.	0.3	22
29	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1153-1168.	2.5	62
30	Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report. <i>Journal of Autoimmunity</i> , 2018, 93, 124-130.	3.0	26
31	Antiphosphatidylserine/prothrombin Antibodies in Antiphospholipid Syndrome with Intrauterine Growth Restriction and Preeclampsia. <i>Journal of Rheumatology</i> , 2018, 45, 1263-1272.	1.0	24
32	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. <i>Blood</i> , 2018, 132, 1365-1371.	0.6	573
33	Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 28-39.	2.9	16
34	Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the APREGNANTS study. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 525.e1-525.e12.	0.7	131
35	Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 730-734.	2.5	63
36	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. <i>Journal of Rheumatology</i> , 2017, 44, 1165-1172.	1.0	51

#	ARTICLE	IF	CITATIONS
37	Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block. <i>Clinical Rheumatology</i> , 2017, 36, 1155-1160.	1.0	9
38	Detection of lupus anticoagulant in the era of direct oral anticoagulants. <i>Autoimmunity Reviews</i> , 2017, 16, 173-178.	2.5	71
39	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, Tj ETQq1 1 0.784314 rgBT /Overlock	2.5	107
40	Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 890-898.	1.4	49
41	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. <i>Immunologic Research</i> , 2017, 65, 17-24.	1.3	97
42	Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. <i>Joint Bone Spine</i> , 2017, 84, 169-173.	0.8	25
43	Maternal autoantibody profiles at risk for autoimmune congenital heart block: a prospective study in high-risk patients. <i>Lupus Science and Medicine</i> , 2016, 3, e000129.	1.1	16
44	Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. <i>Journal of Reproductive Immunology</i> , 2016, 115, 14-19.	0.8	49
45	Inherited thrombophilia in women with poor aPL-related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort. <i>American Journal of Reproductive Immunology</i> , 2016, 76, 164-171.	1.2	14
46	The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study. <i>Joint Bone Spine</i> , 2016, 83, 167-171.	0.8	22
47	Erosive osteoarthritis, psoriatic arthritis and pseudogout; a casual association?. <i>Clinical Rheumatology</i> , 2016, 35, 1885-1889.	1.0	5
48	Plasmapheresis, intravenous immunoglobulins and bethametasone - a combined protocol to treat autoimmune congenital heart block: a prospective cohort study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 706-13.	0.4	23
49	Plasma exchange effectively removes 52 kDa and 60 kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block. <i>Transfusion</i> , 2015, 55, 1782-1786.	0.8	24
50	Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block. <i>Transfusion and Apheresis Science</i> , 2015, 53, 269-278.	0.5	17
51	Inefficacy of plasma exchanges associated to rituximab in refractory obstetrical antiphospholipid syndrome. <i>Presse Medicale</i> , 2015, 44, 100-102.	0.8	10
52	Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. <i>Clinica Chimica Acta</i> , 2015, 446, 201-205.	0.5	38
53	A contribution to detection of anticardiolipin and anti-Î²2glycoprotein I antibodies: Comparison between a home-made ELISA and a fluorescence enzyme immunoassay. <i>Clinica Chimica Acta</i> , 2015, 446, 93-96.	0.5	6
54	The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2015, 14, 498-502.	2.5	152

#	ARTICLE	IF	CITATIONS
55	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. <i>Autoimmunity Reviews</i> , 2015, 14, 387-395.	2.5	121
56	The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome. <i>Thrombosis Research</i> , 2015, 136, 883-886.	0.8	15
57	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2015, 14, 192-200.	2.5	118
58	Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. <i>Thrombosis Research</i> , 2015, 135, 46-49.	0.8	70
59	Obstetrical APS: Is there a place for hydroxychloroquine to improve the pregnancy outcome?. <i>Autoimmunity Reviews</i> , 2015, 14, 23-29.	2.5	62
60	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , 2014, 13, 281-291.	2.5	166
61	Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. <i>Thrombosis and Haemostasis</i> , 2014, 112, 727-735.	1.8	102
62	A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. <i>Autoimmunity Reviews</i> , 2013, 12, 768-773.	2.5	41
63	Treatment of 139 Pregnancies in Antiphospholipid-positive Women Not Fulfilling Criteria for Antiphospholipid Syndrome: A Retrospective Study. <i>Journal of Rheumatology</i> , 2013, 40, 425-429.	1.0	54
64	Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2013, 109, 901-908.	1.8	37
65	What Have We Learned about Antiphospholipid Syndrome from Patients and Antiphospholipid Carrier Cohorts?. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 322-327.	1.5	57
66	A combination therapy to treat second-degree anti-Ro/La-related congenital heart block. A strategy to avoid stable third-degree heart block?. <i>Lupus</i> , 2012, 21, 666-671.	0.8	36
67	Risk-based secondary prevention of obstetric antiphospholipid syndrome. <i>Lupus</i> , 2012, 21, 741-743.	0.8	8
68	Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. <i>Journal of Clinical Apheresis</i> , 2012, 27, 200-204.	0.7	32
69	Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. <i>Blood</i> , 2011, 118, 4714-4718.	0.6	404
70	Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. <i>Rheumatology</i> , 2011, 50, 1684-1689.	0.9	193
71	Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1083-1086.	0.5	178
72	Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. <i>Arthritis Care and Research</i> , 2010, 62, 302-307.	1.5	105

#	ARTICLE	IF	CITATIONS
73	Congenital Heart Block Not Associated with Anti-Ro/La Antibodies: Comparison with Anti-Ro/La-positive Cases. <i>Journal of Rheumatology</i> , 2009, 36, 1744-1748.	1.0	25
74	Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature. <i>Autoimmunity Reviews</i> , 2009, 8, 297-301.	2.5	30
75	Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis. <i>Rheumatology International</i> , 2009, 29, 891-895.	1.5	5
76	Case Reports of the Use of Immunoabsorption or Plasma Exchange in High-Risk Pregnancies of Women With Antiphospholipid Syndrome. <i>Therapeutic Apheresis and Dialysis</i> , 2009, 13, 157-160.	0.4	27
77	Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1693-1696.	1.9	123
78	Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. <i>Autoimmunity Reviews</i> , 2007, 6, 196-202.	2.5	71
79	Unstabilized DNA Breaks in Lymphocytes of Patients with Different Subsets of Systemic Sclerosis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 240-248.	1.8	5
80	Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. <i>Thrombosis and Haemostasis</i> , 2006, 96, 337-341.	1.8	156
81	Unstabilized DNA breaks in lymphocytes of patients with systemic sclerosis. <i>European Journal of Dermatology</i> , 2006, 16, 258-61.	0.3	4
82	Anti-SSA/Ro-related congenital heart block in two family members of different generations: Comment on the article by Clancy et al. <i>Arthritis and Rheumatism</i> , 2005, 52, 1623-1625.	6.7	11
83	Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. <i>Lupus</i> , 2005, 14, 120-128.	0.8	14
84	Sensitivity and specificity for primary Sjögren's syndrome of IgA and IgG anti-alpha-fodrin antibodies detected by ELISA. <i>Journal of Rheumatology</i> , 2004, 31, 504-7.	1.0	22
85	Calcification of the Atrioventricular Node in a Fetus Affected by Congenital Complete Heart Block. <i>Circulation</i> , 2002, 105, 1254-1255.	1.6	20
86	Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. <i>Journal of Rheumatology</i> , 2002, 29, 918-23.	1.0	27
87	Correction for age of anticardiolipin antibodies cut-off points. <i>Journal of Clinical Laboratory Analysis</i> , 2000, 14, 87-90.	0.9	32
88	Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study. <i>Journal of Perinatology</i> , 0, , .	0.9	2